Archives

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United States Egetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® Rare FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval Egetis to […]

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United States Egetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® Rare FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval Egetis to […]

Första och enda FDA-godkända behandlingen av perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis lanserar Egetis RareLink™, ett patientstödsprogram för EMCITATE, i samarbete med PANTHERx® Rare FDA har tilldelat Egetis en Rare Pediatric Disease Priority Review Voucher (PRV) i samband med godkännandet Egetis kommer att hålla en telefonkonferens och webbsändning för […]

Stockholm, Sweden, September 4, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that clinical data relating to Emcitate® (tiratricol) for the treatment of MCT8 deficiency will be presented at the upcoming 47th Annual Meeting of the European Thyroid Association (ETA) in Porto, Portugal, and at the European Society for […]

Stockholm, den 4 september 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att kliniska data avseende Emcitate® (tiratrikol) för behandling av MCT8-brist kommer att presenteras vid den kommande 47:e årskongressen för European Thyroid Association (ETA) i Porto, Portugal, samt vid European Society for Paediatric Endocrinologys (ESPE) 64:e årskongress i Marseille, […]

STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in September.  Cantor Global Healthcare Conference 2026Date: Friday, September 11, 2026Location: Waldorf Astoria, New YorkFormat: Fireside chat and 1-1 meetings Nicklas Westerholm, CEO, will participate in a […]

Stockholm, Sweden, September 3, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that it will participate in upcoming investor conferences in September. Cantor Global Healthcare Conference 2026Date: Friday, September 11, 2026Location: Waldorf Astoria, New YorkFormat: Fireside chat and 1-1 meetings Nicklas Westerholm, CEO, will participate in a fireside chat, […]

Stockholm, 3 september, 2026. Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (Nasdaq Stockholm: EGTX) meddelade idag att Bolaget kommer att delta vid kommande investerarkonferenser i september. Cantor Global Healthcare Conference 2026Datum: Fredag den 11 september 2026Plats: Waldorf Astoria, New YorkFormat: Fireside chat och enskilda investerarmöten (1-on-1)Nicklas Westerholm, vd, kommer att delta i en fireside chat […]

Stockholm, Sweden, August 31, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that its partner Fujimoto Pharmaceutical Corporation, which has an exclusive license agreement to develop and commercialize Emcitate® (tiratricol) for the treatment of MCT8 deficiency in Japan, has been granted Orphan Drug Designation (ODD) for tiratricol for MCT8 […]

Stockholm, 31 augusti, 2026. Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (NASDAQ Stockholm: EGTX) meddelade idag att dess partner Fujimoto Pharmaceutical Corporation, som innehar en exklusiv licens för att utveckla och kommersialisera Emcitate® (tiratricol) för behandling av MCT8-brist i Japan, har beviljats särläkemedelsstatus (Orphan Drug Designation, ODD) för tiratricol vid MCT8-brist av Japans hälso-, arbetsmarknads- […]